Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity

Blood

Volumn 108, Issue 8, 2006, Pages 2545-2553

  Modlich, Ute ^b   Bohne, Jens ^b   Schmidt, Manfred ^b   Von Kalle, Christof ^b   Knöss, Sabine ^b   Schambach, Axel ^b   Baum, Christopher ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENHANCER REGION; GENE INSERTION; GENE INTERACTION; GENE TRANSFER; GENETIC TRANSDUCTION; GENOTOXICITY; HEMATOPOIETIC CELL; LEUKEMIA; LONG TERMINAL REPEAT; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; RETROVIRUS VECTOR; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CULTURE TECHNIQUE; CYTOLOGY; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IN VITRO STUDY; METHODOLOGY; RETROVIRUS; SAFETY; VIROLOGY;

VIRUS DNA;

ANIMALS; BASE SEQUENCE; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; DNA, VIRAL; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; LEUKEMIA; MICE; MICE, INBRED C57BL; MUTAGENESIS, INSERTIONAL; PROTO-ONCOGENES; RETROVIRIDAE; SAFETY; TERMINAL REPEAT SEQUENCES; TRANSDUCTION, GENETIC;

EID: 33750624015     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-024976     Document Type: Article

References (32)

1. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185-1193.
2. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413.
3. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181-2187.
4. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401-409.
5. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346-358.
6. Baum C, Dullmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;101:2099-2114.
7. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science. 2002;296:497.
8. Modlich U, Kustikova O, Schmidt M, et al. Leukemias following retroviral transfer of multidrug resistance 1 are driven by combinatorial insertional mutagenesis. Blood. 2005;105:4235-4246.
9. Seggewiss R, Pittaluga S, Adler RL, et al. Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood. 2006;107:3865-3867.
10. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-419.
11. Mikkers H, Berns A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res. 2003;88:53-99.
12. Kustikova OS, Fehse B, Modlich U, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 2005;308:1171-1174.
13. Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 2005;106:3932-3939.
14. Schambach A, Wodrich H, Hildinger M, Bohne J, Krausslich HG, Baum C. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther. 2000;2:435-445.
15. 6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther. 2006;13:391-400.
16. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7:1063-1070.
17. Li Z, Schwieger M, Lange C, et al. Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol. 2003;31:1206-1214.
18. Schmidt M, Hoffmann G, Wissler M, et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther. 2001;12:743-749.
19. Schmidt M, Zickler P, Hoffmann G, et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 2002;100:2737-2743.
20. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004;32:D523-D527.
21. Nucifora G, Laricchia-Robbio L, Senyuk V. EVI1 and hematopoietic disorders: history and perspectives. Gene. 2006;368:1-11.
22. Milsom MD, Fairbairn LJ. Protection and selection for gene therapy in the hematopoietic system. J Gene Med. 2004;6:133-146.
23. Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of HIV-1 entry in cells expressing Gp41-derived peptides. J Virol. 2004;78:568-575.
24. Wolkowicz R, Nolan GP. Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene Ther. 2005;12:467-476.
25. Emery DW, Yannaki E, Tubb J, Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A. 2000;97:9150-9155.
26. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749-1751.
27. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004;2:e423.
28. Calmels B, Ferguson C, Laukkanen MO, et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood. 2005;106:2530-2533.
29. Ailles LE, Naldini L. HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol. 2002;261:31-52.
30. Stocking C, Bergholz U, Friel J, et al. Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. Growth Factors. 1993;8:197-209.
31. + cells, but impairs lymphomyeloid differentiation. Blood. 2003;101:1759-1768.
32. Boyd KE, Xiao YY, Fan K, et al. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. Blood. 2006;107:733-741.